Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Nature Communications|November 27, 2021
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunizationDennis Lapuente, Jana Fuchs, Jonas Willar, et al.
Science Immunology|December 22, 2022
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccinationPascal Irrgang, Juliane Gerling, Katharina Kocher, et al.
Viruses|July 2, 2021
Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020Ralf Wagner, David Peterhoff, Stephanie Beileke, et al.
Nature Communications|April 26, 2020
Ethanol consumption inhibits T<sub>FH</sub> cell responses and the development of autoimmune arthritisVugar Azizov, Katharina Dietel, Franziska Steffen, et al.
Frontiers in Immunology|January 9, 2023
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variantNatalie Heinen, Corinna Sophie Marheinecke, Clara Bessen, et al.
Journal of Medicinal Chemistry|June 3, 2026
DHODH Inhibitors Based on the Vidofludimus Scaffold Containing Carboxylic Acid Bioisosteres Exert a Superior Broad-Spectrum Antiviral ActivityAlexandra Herrmann, Friedrich Hahn, Christina Wangen, et al.
Antiviral Research|September 21, 2024
Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activityAlexandra Herrmann, Christian Gege, Christina Wangen, et al.
Plos Pathogens|April 1, 2020
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyPaul David, Malgorzata Drabczyk-Pluta, Eva Pastille, et al.
Ebiomedicine|October 7, 2022
Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2Emanuel Vogel, Katharina Kocher, Alina Priller, et al.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
Pageof 9